Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm

Ustekinumab Pricing Bites; Cimerli ‘Paused’; Pembrolizumab Phase III Terminated

 
• By Dave Wallace
  
Formycon is facing stormy market conditions in biosimilars (Shutterstock)

More from Biosimilars

More from Policy & Regulation